QS Investors LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,583 shares of the biotechnology company’s stock after selling 3,367 shares during the period. QS Investors LLC owned 0.36% of Repligen worth $5,717,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Repligen during the 3rd quarter worth approximately $180,000. Crossmark Global Holdings Inc. acquired a new position in shares of Repligen during the 3rd quarter worth approximately $241,000. Brown Advisory Inc. acquired a new position in shares of Repligen during the 3rd quarter worth approximately $310,000. First Manhattan Co. boosted its holdings in shares of Repligen by 16.7% during the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Repligen during the 4th quarter worth approximately $462,000. Institutional investors and hedge funds own 87.60% of the company’s stock.
RGEN has been the topic of several recent research reports. BidaskClub cut Repligen from a “hold” rating to a “sell” rating in a report on Wednesday, February 7th. Citigroup initiated coverage on Repligen in a report on Friday, December 8th. They set a “buy” rating and a $45.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of Repligen in a research report on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 24th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $44.38.
Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.08. The firm had revenue of $41.60 million for the quarter, compared to analyst estimates of $41.13 million. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The business’s revenue for the quarter was up 62.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 EPS. analysts forecast that Repligen Co. will post 0.7 earnings per share for the current year.
In other news, Director Thomas F. Ryan, Jr. sold 4,696 shares of Repligen stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total transaction of $169,807.36. Following the sale, the director now owns 9,700 shares of the company’s stock, valued at approximately $350,752. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Howard Benjamin sold 12,729 shares of Repligen stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the sale, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,395 shares of company stock worth $942,122. Corporate insiders own 1.50% of the company’s stock.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.